MNKD Mannkind

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.

Company profile

Michael Castagna
Fiscal year end
IRS number

MNKD stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


12 May 21
2 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Mannkind earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 247.99M 247.99M 247.99M 247.99M 247.99M 247.99M
Cash burn (monthly) (positive/no burn) (positive/no burn) 4.31M 5.09M 4.24M 2.47M
Cash used (since last report) n/a n/a 17.64M 20.85M 17.39M 10.12M
Cash remaining n/a n/a 230.35M 227.14M 230.6M 237.87M
Runway (months of cash) n/a n/a 53.5 44.6 54.3 96.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
30 Jul 21 Michael Castagna Common Stock, $0.01 Par Value Buy Aquire P No No 2.99 5,000 14.95K 1,538,652
30 Jul 21 Steven B. Binder Common Stock, $0.01 Par Value Buy Aquire P No No 2.99 748 2.24K 547,644
30 Jul 21 Stuart A Tross Common Stock, $0.01 Par Value Buy Aquire P No No 2.99 4,476 13.38K 634,708
30 Jul 21 Alejandro Galindo Common Stock, $0.01 Par Value Buy Aquire P No No 2.99 5,000 14.95K 547,602
20 May 21 Friedman Michael A RSU Common Stock Grant Aquire A No No 0 33,860 0 33,860

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

42.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 159 146 +8.9%
Opened positions 31 29 +6.9%
Closed positions 18 19 -5.3%
Increased positions 59 52 +13.5%
Reduced positions 33 36 -8.3%
13F shares
Current Prev Q Change
Total value 882.77M 446.41M +97.8%
Total shares 106.84M 75.1M +42.3%
Total puts 1.61M 1.37M +17.6%
Total calls 1.32M 969.8K +36.3%
Total put/call ratio 1.2 1.4 -13.7%
Largest owners
Shares Value Change
BLK Blackrock 18.76M $73.54M +4.4%
STT State Street 16.21M $63.54M +83.2%
Vanguard 13.18M $51.68M +7.3%
Avoro Capital Advisors 7.5M $29.4M +114.3%
FMR 4.45M $17.43M +19.1%
Citadel Advisors 4.06M $15.92M +477.3%
Geode Capital Management 3.84M $15.04M +16.7%
Two Sigma Advisers 2.89M $11.33M +98.5%
Millennium Management 2.88M $11.28M +39.0%
NTRS Northern Trust 2.42M $9.5M -4.1%
Largest transactions
Shares Bought/sold Change
STT State Street 16.21M +7.36M +83.2%
Avoro Capital Advisors 7.5M +4M +114.3%
Citadel Advisors 4.06M +3.36M +477.3%
Eversept Partners 2.17M +2.17M NEW
Two Sigma Advisers 2.89M +1.43M +98.5%
IVZ Invesco 1.45M +1.41M +3561.4%
Schonfeld Strategic Advisors 1.39M +1.34M +2425.2%
C Citigroup 1.04M +992.77K +1929.1%
Vanguard 13.18M +892.42K +7.3%
Bruce & Co. 895.07K +863.24K +2711.6%

Financial report summary

  • We are currently dependent on the successful commercialization of our only approved product, Afrezza. The continued commercialization and development of Afrezza will require substantial capital that we may not be able to obtain.*
  • If we fail as an effective manufacturing organization, we may be unable to support commercialization of Afrezza or Tyvaso DPI.*
  • We expect that our results of operations will fluctuate for the foreseeable future, which may make it difficult to predict our future performance from period to period.*
  • Our business, product sales, results of operations and ability to access capital could be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic, in regions where we or third parties distribute our products or where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations. The COVID-19 pandemic could materially affect our operations, including at our headquarters in California and at our manufacturing facility in Connecticut and with respect to our sales force and their ability to interact with health care professionals, as well as the business or operations of our suppliers, distributors or other third parties with whom we conduct business.*
  • If we do not obtain regulatory approval of Afrezza in foreign jurisdictions, we will not be able to market Afrezza in such jurisdictions, which could limit our commercial revenues. We may not be able to establish additional regional partnerships or other arrangements with third parties for the commercialization of Afrezza outside of the United States.*
  • We may not be successful in our efforts to develop and commercialize our product candidates.*
  • We have a history of operating losses, we expect to incur losses in the future and we may not generate positive cash flow from operations in the future.*
  • We have a substantial amount of debt, and we may be unable to make required payments of interest and principal as they become due.*
  • If we do not achieve our projected development goals in the timeframes we expect, our business, financial condition and results of operations will be harmed and the market price of our common stock and other securities could decline.
  • Continued testing of Afrezza or our product candidates may not yield successful results, and even if it does, we may still be unable to commercialize our product candidates.
  • If our suppliers fail to deliver materials and services needed for commercial manufacturing in a timely and sufficient manner or fail to comply with applicable regulations, and if we fail to timely identify and qualify alternative suppliers, our business, financial condition and results of operations would be harmed and the market price of our common stock and other securities could decline.
  • If Afrezza or any other product that we develop does not become widely accepted by physicians, patients, third-party payers and the healthcare community, we may be unable to generate significant revenue, if any.
  • If third-party payers do not cover Afrezza or any of our product candidates for which we receive regulatory approval, Afrezza or such product candidates might not be prescribed, used or purchased, which would adversely affect our revenues.
  • If product liability claims are brought against us, we may incur significant liabilities and suffer damage to our reputation.
  • If we lose any key employees or scientific advisors, our operations and our ability to execute our business strategy could be materially harmed.
  • If our internal controls over financial reporting are not considered effective, our business, financial condition and market price of our common stock and other securities could be adversely affected.
  • Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or non-realization of expected benefits.
  • We may undertake internal restructuring activities in the future that could result in disruptions to our business or otherwise materially harm our results of operations or financial condition.
  • We and certain of our executive officers and directors have been named as defendants in ongoing securities lawsuits that could result in substantial costs and divert management’s attention.
  • Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.
  • We deal with hazardous materials and must comply with environmental laws and regulations, which can be expensive and restrict how we do business.
  • We are increasingly dependent on information technology systems, infrastructure and data security.
  • Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
  • The withdrawal of the United Kingdom from the European Union, commonly referred to as “Brexit,” may adversely impact our ability to obtain regulatory approvals of our product candidates in the European Union, result in restrictions or imposition of taxes and duties for importing our product candidates into the European Union, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the European Union.
  • If we do not comply with regulatory requirements at any stage, whether before or after marketing approval is obtained, we may be fined or forced to remove a product from the market, subject to criminal prosecution, or experience other adverse consequences, including restrictions or delays in obtaining regulatory marketing approval.
  • We are subject to stringent, ongoing government regulation.
  • Healthcare legislation may make it more difficult to receive revenues.
  • If we or any future marketing partner fails to comply with federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.
  • If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the United States, we could be subject to additional reimbursement requirements, fines, sanctions and exposure under other laws which could have a material adverse effect on our business, results of operations and financial condition.
  • Reports of side effects or safety concerns in related technology fields or in other companies’ clinical studies could delay or prevent us from obtaining regulatory approval for our product candidates or negatively impact public perception of Afrezza or any other products we may develop.
  • If we become involved in lawsuits to protect or enforce our patents or the patents of our collaborators or licensors, we would be required to devote substantial time and resources to prosecute or defend such proceedings.
  • If our technologies conflict with the proprietary rights of others, we may incur substantial costs as a result of litigation or other proceedings and we could face substantial monetary damages and be precluded from commercializing our products, which would materially harm our business and financial condition.
  • We may not obtain trademark registrations for our potential trade names.
  • Our stock price is volatile and may affect the market price of our common stock and other securities.*
  • Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
  • Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America are the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
  • Because we do not expect to pay dividends in the foreseeable future, you must rely on stock appreciation for any return on any investment in our common stock.
  • Future sales of shares of our common stock in the public market, or the perception that such sales may occur, may depress our stock price and adversely impact the market price of our common stock and other securities.
  • If other biotechnology and biopharmaceutical companies or the securities markets in general encounter problems, the market price of our common stock and other securities could be adversely affected.
Content analysis
H.S. senior Avg
New words: accommodate, anesthesiologist, antidilutive, backlog, batch, Biden, binomial, Britain, build, built, Canada, centralized, children, Columbia, consecutive, constitutionality, contrast, convey, conveyance, decision, diketopiperazine, disbursement, DPI, EMA, EPS, ESPP, expressly, factor, feature, fulfill, fumaryl, Great, heading, hypothetical, hypothyroidism, innovator, Issuer, ix, joinder, joined, Kingdom, learn, lesser, lieu, MHRA, midst, nationwide, Northern, nurse, open, overturning, paper, par, payer, pediatric, perspective, Pharma, Portability, preliminary, proportion, QrumPharma, redemption, reexamining, regime, regular, Rescue, risky, sinking, speculative, straight, surviving, tariff, team, thereon, Thyquidity, tie, transferee, Tyvaso, UK, unaccrued, unbilled, unconstrained, undesignated, undiscounted, unnecessary, usability, vaccination, Vertice, vi, vii, viii, voucher, waiver, withdrew, worth
Removed: acquired, allegation, allotted, assemble, banking, base, begin, Bellina, beneficiary, biosimilar, Blueprint, calculating, calling, cancellation, capability, CECL, certiorari, CLA, clarify, closed, codified, compound, considerable, consulting, death, discharge, distributed, dividend, enrolling, Europe, expiry, extended, feasibility, Frank, grow, growing, hour, incentivize, inclusion, indemnity, influence, instability, intraperiod, Jordan, judgement, mandatorily, Matthew, McLinn, methodology, Mongiello, negotiating, origination, output, participant, payor, permission, permitting, pocket, point, possession, professional, pronouncement, proposal, prototype, rank, recall, recapitalization, Receptor, recording, release, repayment, resignation, retirement, runway, separation, simplify, solicited, solvency, stating, step, television, TreT, Trickett, undergoing, underperform, unprecedented, utilize, vest, week, Wendler, wider


Heat-stable dry powder pharmaceutical compositions and methods
25 May 21
Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition.
Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
25 May 21
Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent.
Use of ultrarapid acting insulin
25 May 21
Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
Dry Powder Inhaler
20 May 21
A dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed.
Method of Treating Diabetes Type 2 by Administering Ultrarapid Acting Insulin
13 May 21
Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.